The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of NAD(P)H quinone oxidoreductase (NQO1) expression as a predictive factor for adjuvant chemotherapy benefit in patients with early breast cancer.
Monica Arnedos
No relevant relationships to disclose
Aicha Goubar
No relevant relationships to disclose
Kam M. Sprott
Employment or Leadership Position - On-Q-ity
Stock Ownership - On-Q-ity
Chunsheng Jiang
Employment or Leadership Position - On-Q-ity
Stock Ownership - On-Q-ity
Jessica Suschak
Employment or Leadership Position - On-Q-ity
Stock Ownership - On-Q-ity
David T. Weaver
Employment or Leadership Position - On-Q-ity
Stock Ownership - On-Q-ity
Suzette Delaloge
No relevant relationships to disclose
Rosa Conforti
No relevant relationships to disclose
Fabrice Andre
No relevant relationships to disclose